APLP2 Human shRNA Plasmid Kit (Locus ID 334)

Specifications

Product Data
Product Name	APLP2 Human shRNA Plasmid Kit (Locus ID 334)
Locus ID	334
UniProt ID	Q06481
Synonyms	APLP-2; APPH; APPL2; CDEBP
Vector	pGFP-V-RS
Format	Retroviral plasmids
Kit Components	APLP2 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 334). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.
RefSeq	BC004371, NM_001142276, NM_001142277, NM_001142278, NM_001243299, NM_001642, NR_024515, NR_024516, NM_001328682, NM_001328684, NM_001328685, NM_001328686, NM_001642.1, NM_001642.2, NM_001142276.1, NM_001142277.1, NM_001142278.1, NM_001243299.1, BC004371.1, BC000373, BM992563, NM_001142278.2, NM_001642.3, NM_001142277.2, NM_001142276.2
Summary	This gene encodes amyloid precursor- like protein 2 (APLP2), which is a member of the APP (amyloid precursor protein) family including APP, APLP1 and APLP2. This protein is ubiquitously expressed. It contains heparin-, copper- and zinc- binding domains at the N-terminus, BPTI/Kunitz inhibitor and E2 domains in the middle region, and transmembrane and intracellular domains at the C-terminus. This protein interacts with major histocompatibility complex (MHC) class I molecules. The synergy of this protein and the APP is required to mediate neuromuscular transmission, spatial learning and synaptic plasticity. This protein has been implicated in the pathogenesis of Alzheimer's disease. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.